Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05178303 · ClinicalTrials.gov registry record · Phase 4
Composition for Treating Cirrhosis and Liver Cancer (SB-1121)
A Phase 4 study of Cirrhosis of the Liver, sponsored by Nguyen Thi Trieu, MD.
- Completed
- Registry status
- Phase 4
- Development phase
- 134
- Enrollment target
- 2
- Study locations
NCT05178303: Completed Phase 4 study of Cirrhosis of the Liver, sponsored by Nguyen Thi Trieu, MD.
NCT05178303 is a Phase 4 study of Cirrhosis of the Liver that has completed, run by Nguyen Thi Trieu, MD. The registered enrollment target is 134 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05178303, a Phase 4 study of Cirrhosis of the Liver, has completed, sponsored by Nguyen Thi Trieu, MD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 134 participants
- Enrollment target
- 2
- Study locations
Study Summary
The composition treats cirrhosis and hepatocellular carcinoma (Hcc) at an early stage. The product is extracted from herbs, including Adenosma glutinosum extract, Eclipta prostrata extract, Phyllanthus urinaria extract, Impatiens balsamina extract, Ascorbic acid, pyridoxine 5-phosphate, L-Arginine hydrochloride, Pregnenolone acetate. These components have participated in repairing and regenerating new liver parenchyma, preventing fibrosis cell generation, preventing liver cancer cell growth at an early stage. The composition supplements precursors which help the body strengthen antibodies and reduce the risk of inflammation, restore physiological and biochemical functions of liver cells after chronic inflammation.
Primary Outcome
HBV, HCV,... injure healthy liver cells, causing cell death and inflammation. Healthy liver tissue is replaced with scar tissue and the liver is damaged.
Conditions Studied
Interventions
- DRUG SB-1121(1)
- DRUG SB-1121(2)
Study Locations (2)
Delaware
- Saigon Biopharma LLC - Wilmington
Other
- Saigon Biopharma Company Limited - Ho Chi Minh City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2015-11-30 |
| Est. Completion | 2021-11-10 |
| Phase | Phase 4 |
What the finished NCT05178303 record still lists
NCT05178303 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Cirrhosis of the Liver appearing as the primary indexed condition, and to 2 interventions - of which SB-1121(1) is the first listed.
NCT05178303 reports a single indexed study location in Delaware, Other.
Frequently Asked Questions
What is clinical trial NCT05178303 about?
NCT05178303 is a clinical study titled "Composition for Treating Cirrhosis and Liver Cancer (SB-1121)". The composition treats cirrhosis and hepatocellular carcinoma (Hcc) at an early stage. The product is extracted from herbs, including Adenosma glutinosum extract, Eclipta prostrata extract, Phyllanthus urinaria extract, Impatiens balsamina extract, Ascorbic acid, pyridoxine 5-phosphate, L-Arginine h...
What is the current status of trial NCT05178303?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 134 participants. The study started on 2015-11-30. Estimated completion is 2021-11-10.
What conditions does trial NCT05178303 study?
This clinical trial studies the following conditions: Cirrhosis of the Liver.
What interventions are being tested in trial NCT05178303?
The interventions under investigation include: SB-1121(1) (DRUG), SB-1121(2) (DRUG).
Who is sponsoring clinical trial NCT05178303?
This trial is sponsored by Nguyen Thi Trieu, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05178303 being conducted?
This trial has 2 study locations across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05178303's enrollment target sits among peer trials
134 606th of 2000 higher than 1,391 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI